Renal Denervation
Definition
Renal denervation (RDN) is a catheter-based procedure that ablates the renal sympathetic nerves to reduce blood pressure by suppressing sympathetic outflow to the kidney. FDA-approved in November 2023 as an adjunctive treatment for patients with uncontrolled hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. (sources/rnd-aha-2024, rating: high)
Key Concepts
Physiological Basis
- Renal sympathetic nerves regulate BP through three level-dependent mechanisms (sources/rnd-aha-2024, rating: high):
- Low activation: renin release
- Moderate activation: sodium reabsorption (antinatriuresis)
- High activation: increased renal vascular resistance
- Knowledge of renal nerve physiology dates to mid-1800s; percutaneous methods developed after work with direct electrical stimulation and complete surgical denervation
Device Types and Mechanisms
Three main RDN systems have been studied (sources/rnd-aha-2024, rating: high):
| System | Manufacturer | Mechanism | FDA Status |
|---|---|---|---|
| Symplicity Spyral | Medtronic | Radiofrequency — 4-electrode spiral catheter delivering medium-frequency AC current, heating periadventitial space without arterial wall injury | Approved Nov 2023 |
| Paradise System | Recor Medical | Intravascular ultrasound via balloon catheter with simultaneous luminal cooling (protects arterial wall) | Approved Nov 2023 |
| Peregrine System | Ablative Solutions | Chemical — dehydrated alcohol injected via 3 microneedles into the perivascular space | Not FDA-approved |
- Earlier RF prototypes (Symplicity Flex monoelectrode, Vessix bipolar) caused incomplete denervation — now superseded
- More extensive denervation (incorporating branching/accessory renal arteries in addition to main arteries) in newer protocols improves outcomes
Efficacy — Drug-Naive / Washout Patients
- 6 RCTs with ambulatory SBP endpoints at 2–3 months (sources/rnd-aha-2024, rating: high):
- SPYRAL OFF-MED Pivotal (n=331, Spyral): −4.7 mmHg 24h SBP vs −0.6 mmHg sham (p<0.01)
- RADIANCE-HTN SOLO (n=146, Paradise): −8.5 mmHg daytime SBP vs −2.2 mmHg sham (p<0.01)
- RADIANCE II (n=150, Paradise): −7.9 mmHg vs −1.8 mmHg sham (p<0.01); office SBP −5.5 mmHg in both SOLO and RADIANCE II
- REDUCE HTN: REINFORCE (n=51, Vessix): No difference
- TARGET BP OFF-MED (n=106, Peregrine): No difference at 8 weeks; lower medication burden at 12 months
- Summary: majority of trials positive; BP reduction equivalent to approximately 1 additional antihypertensive drug
Efficacy — Patients on 1–5 Antihypertensives
- Results more variable due to medication protocol heterogeneity (sources/rnd-aha-2024, rating: high):
- SPYRAL ON-MED pilot (n=80): RDN superior by 7.4 mmHg 24h SBP (p<0.01)
- SPYRAL ON-MED Expansion (n=257): No significant difference — unexpectedly large sham arm reduction (4.5 mmHg) from protocol-violating medication intensification in sham arm (29.9% vs 17.3%; p=0.02)
- TARGET BP I (n=301, Peregrine): Modest but significant −3.2 mmHg at 3 months (p=0.049)
Efficacy — Resistant Hypertension (RH)
- RH defined as BP above goal on ≥3 drugs (complementary mechanisms, including diuretic) or at goal on ≥4 drugs; prevalence ≈19.7% of treated hypertensive adults; 2× CVD risk (sources/rnd-aha-2024, rating: high)
- 10 sham-controlled RCTs; early trials with Symplicity Flex (unipolar) negative (SYMPLICITY HTN-3, Desch, ReSET) — attributed to incomplete denervation and medication intensification in sham arms
- DENERHTN (standardised triple therapy + adherence monitoring): −5.9 mmHg daytime SBP (95% CI −11.3 to −0.5; p=0.03)
- RADIANCE-HTN TRIO (standardised triple-pill): −4.5 mmHg daytime SBP (95% CI −8.5 to −0.3; p=0.02)
- RADIOSOUND-HTN (only head-to-head trial): Ultrasound-based RDN (Paradise, −13.2 mmHg daytime) > radiofrequency main-artery alone (−6.7 mmHg) or main+branch (−8.3 mmHg) at 3 months (p=0.04)
- Unipolar RF vs spironolactone: RDN inferior or equivalent (DENERVHTA, Prague-15)
- Global SYMPLICITY Registry (3 years, no sham control): office SBP −16.5±28.6 mmHg; 24h ambulatory SBP −8.0±20.0 mmHg — sustained but uncontrolled data
Overall Response Rate
- 60–70% of patients achieve a meaningful ≥5 mmHg reduction in office or daytime ambulatory SBP within 2–3 months of ultrasound RDN (sources/rnd-aha-2024, rating: high)
- 24% of RDN patients achieve target daytime/home BP <135/85 mmHg vs 12% sham, with lower medication burden in the RDN arm
- Higher baseline BP is the most consistent predictor of greater BP reduction; no other clinical predictor reliably validated
Patient Selection Framework
Indications (sources/rnd-aha-2024, rating: high):
- Sustained, uncontrolled hypertension confirmed with 24h ABPM or appropriate home BP (to exclude white-coat hypertension)
- True resistant hypertension (≥3 drugs including diuretic above goal, or ≥4 drugs to maintain goal)
- Uncontrolled BP despite medication intolerance, non-adherence, or inability to escalate therapy
Absolute contraindications:
- Pregnancy
- Fibromuscular dysplasia
- Stented renal artery
- Renal artery aneurysm
- Significant renal artery stenosis (>50%)
- Known kidney or adrenal-secreting tumour
Limited data / use with caution:
- Stage 1 hypertension
- Isolated systolic hypertension
- Stage 4–5 CKD
- Single kidney
- Kidney transplant recipients
Mandatory pre-procedure workup:
- Serum creatinine + urinalysis (eGFR ≥40 mL/min/1.73m² required in most RCTs)
- Universal screening for primary aldosteronism (present but often undiagnosed; normal K⁺ does not exclude it)
- Based on clinical suspicion: hormonal testing (Cushing, phaeochromocytoma, thyroid, hyperparathyroidism), imaging (RAS, fibromuscular dysplasia, aortic coarctation)
Safety Profile
- Procedure via femoral artery access; duration ≈1 hour (sources/rnd-aha-2024, rating: high)
- Procedural risks: same as standard femoral arterial access (haemorrhage, infection, arterial dissection, thromboembolism, AV fistula, pseudoaneurysm, contrast, radiation)
- Serious adverse events <1% (renal artery dissection, access site complications, death)
- Most common adverse event: pain lasting >2 days post-procedure (12%)
- No deleterious effect on kidney function — including in moderate-to-severe CKD and systolic HF
- Renal artery stenosis post-procedure: estimated incidence 0.2%/year; similar to natural rate in hypertensive patients; greatest risk within first 6 months
- 3-year Global SYMPLICITY Registry: no late safety signals
- Reinnervation: Animal models show partial/full reinnervation with persistent BP reduction — functional significance in humans unclear; theoretical concern remains
Response Variability and Durability
- Factors associated with attenuated response: lower baseline BP, higher arterial stiffness, anatomical variants (accessory arteries), development of comorbidities, aging, medication changes (sources/rnd-aha-2024, rating: high)
- Some patients exhibit partial response or return to baseline values over time
- Proposed but unvalidated predictors of greater response: higher sympathetic activity markers (BP variability, resting heart rate, renin), orthostatic hypertension
Shared Decision-Making and Patient Expectations
- ≈30% of medicated patients and 35–40% of unmedicated patients globally are interested in RDN (sources/rnd-aha-2024, rating: high)
- Patient expectation gap: >96% expect ≥10 mmHg SBP reduction; actual outcomes are 5–10 mmHg; 40% in Germany expect to stop all medications post-RDN
- A 10 mmHg BP reduction is associated with 10–20% decline in CV morbidity/mortality; RDN's 5–10 mmHg reduction could yield similar benefit — no completed CVD outcomes trial
- Multidisciplinary team (hypertension specialist + trained proceduralist: interventional radiologist, interventional cardiologist, or vascular surgeon) required for candidate selection and post-procedure follow-up
- Physician concerns: invasive procedure, limited long-term data, continued medication reliance
ESC 2024 Guideline Recommendations (Upgraded from Class III in 2018)
(sources/ht-esc-2024, rating: very high)
| Indication | Class | Level | Key conditions |
|---|---|---|---|
| Resistant HT (uncontrolled on 3-drug combination incl. diuretic) | IIb | B | Medium-to-high volume centre; patient preference; multidisciplinary assessment |
| Increased CVD risk + uncontrolled HT on <3 drugs | IIb | A | Patient preference; shared risk-benefit discussion |
| First-line BP intervention | III | C | Not recommended regardless of setting |
| eGFR <40 mL/min/1.73 m² or secondary HT causes | III | C | Insufficient evidence |
- 2018 → 2024 change: 2018 ESC guidelines classified all device-based BP therapy as Class III (not recommended); 2024 upgrades RDN to Class IIb based on second-generation sham-controlled trial data
- Comparison with AHA 2025 (COR 2b): Both ESC 2024 and AHA 2025 converge on RDN as an option for carefully selected patients with refractory/resistant hypertension — neither recommends it as routine first or second-line therapy
- Unresolved issue (ESC 2024 explicit): No adequately powered CVD outcomes trial exists; RDN effect (~6 mmHg office SBP, ~4 mmHg 24h ABPM) is equivalent to 1 standard medication and most medications are now generic — cost-effectiveness not established except potentially in high-risk resistant HT with non-adherence
- Renal artery stenosis/dissection requiring stenting: 0.25–0.5%; no long-term sham-controlled safety data beyond 3 years
Contradictions / Open Questions
- ESC 2024 vs AHA 2025 — indication scope: ESC IIb, A for increased CVD risk patients with uncontrolled HT on <3 drugs (broader) vs AHA 2025 COR 2b for resistant HT only — ESC allows consideration earlier in the medication escalation pathway (sources/ht-esc-2024, rating: very high; sources/HT-AHA-2025, rating: very high)
- Inconsistent RCT efficacy: Early trials (SYMPLICITY HTN-3, REDUCE HTN:REINFORCE, TARGET BP OFF-MED) negative; newer trials with better technique, drug surveillance, and sham control largely positive — creates uncertainty about generalising across device types (sources/rnd-aha-2024, rating: high)
- No CVD outcomes data: All RCT endpoints are BP-based; no completed trial demonstrates reduction in MI, stroke, or death
- Spironolactone vs RDN: Two trials (DENERVHTA, Prague-15) show unipolar RF RDN inferior or equivalent to spironolactone as 4th agent — optimal sequencing unclear; MRA + RDN combination not studied (sources/rnd-aha-2024, rating: high; sources/HT-AHA-2025, rating: very high)
- Reinnervation in humans: Animal models show reinnervation with persistent effect; human durability data limited to registry observational data
- Responder identification: No clinical or biomarker predictor reliably identifies prospective responders
- Cost-effectiveness: Unknown vs generic pharmacotherapy, which is now very low cost
Connections
- Related to entities/Hypertension (primary disease entity; RDN as adjunctive treatment)
- Related to concepts/ASCVD-Risk-Assessment (resistant hypertension as high CVD risk state)
- Related to concepts/Cuffless-BP-Monitoring (BP monitoring approach in RDN candidates)
- Related to sources/HT-AHA-2025 (2025 AHA hypertension guideline: RDN COR 2b)